Catalyst Event
Gilead Sciences Inc (GILD) · Other
From KEDI Nvidia Fixed Tech100 Index (KNVDT100)
6/2/2026, 12:00:00 AM
The Phase 3 IDEAL study of Livdelzi (seladelpar) met its primary endpoint on June 2, 2026. This clinical success is estimated to have a ≥5% price impact, scheduled.
Korean Translation
2026년 6월 2일, 리브델지의 3상 IDEAL 연구가 주요 평가변수를 충족함. 주요 파이프라인의 임상 성공으로 5% 이상의 주가 영향이 예상되어 'Medium'으로 분류함, 예정됨.
Related Recent Events
Microchip Technology Inc (MCHP) · Earnings Release
Next quarterly earnings for Q1 2027 are expected to be released around August 6, 2026, expected. Low impact is estimated as this is a routine scheduling announcement.
8/6/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q2 2026 earnings release is expected around August 5, 2026, based on past reporting schedules expected. Low impact estimated as the announcement of a date typically precedes the actual market-moving results.
8/5/2026, 12:00:00 AM
Advanced Micro Devices Inc (AMD) · Earnings Release
Q2 2026 earnings release and conference call scheduled.
8/4/2026, 12:00:00 AM
Super Micro Computer Inc (SMCI) · Earnings Release
The Q4 2026 earnings release is scheduled for August 4, 2026. Low importance is estimated as no market reaction has occurred yet for this future date, expected.
8/4/2026, 12:00:00 AM
Comcast Corp (CMCSA) · Earnings Release
Comcast's Q2 2026 earnings release on July 30, 2026 scheduled. Medium importance is estimated as earnings reports often impact stock prices.
7/30/2026, 12:00:00 AM
KLA Corp (KLAC) · Earnings Release
Fiscal Q4 2026 earnings release on July 30, 2026, is expected to have a medium importance impact on the stock price, scheduled.
7/30/2026, 12:00:00 AM